Previous 10 | Next 10 |
home / stock / invvy / invvy news
Indivior Announces Q3 2022 Financial Results PR Newswire SLOUGH, UK and RICHMOND, Va. , Oct. 27, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced its financial results for the period ending September 30, 2022 . The earnings relea...
The following slide deck was published by Indivior PLC in conjunction with their 2022 Q3 earnings call. For further details see: Indivior PLC 2022 Q3 - Results - Earnings Call Presentation
Indivior Shareholders Approve Resolutions to Proceed with Additional U.S. Listing PR Newswire RICHMOND, Va. , Sept. 30, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that at the General Meeting of Shareholders held earlier today, sharehold...
Indivior To Participate in Upcoming Investor Healthcare Events PR Newswire SLOUGH, United Kingdom and RICHMOND, Va. , Sept. 7, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that it will participate in the following investor healthcare ...
Indivior Recognizes National Recovery Month, Commits to Helping Move People living with Opioid Use Disorder onto a Path to Hope and Recovery PR Newswire RICHMOND, Va. , Sept. 1, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) September is National Recovery ...
Indivior Publishes Exploratory Study Showing That Access to Medication for Opioid Use Disorder Varies Across Organized Health Systems in the U.S. PR Newswire Published in Drug and Alcohol Dependence Reports, the study shows that identifying and overcoming barriers ...
Addex Therapeutics ( NASDAQ: ADXN ) and Indivior ( OTCPK:INVVY ) ( OTCPK:IZQVF ) extended their collaboration on discovering and developing novel oral gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) drug candidates until March 31, 2023...
Indivior PLC (INVVY) Q2 2022 Earnings Conference Call July 28, 2022 08:00 AM ET Company Participants Mark Crossley - Chief Executive Officer Ryan Preblick - Chief Financial Officer Christian Heidbreder - Chief Scientific Officer Conference Call Participants...
The following slide deck was published by Indivior PLC in conjunction with their 2022 Q2 earnings call. For further details see: Indivior PLC 2022 Q2 - Results - Earnings Call Presentation
Indivior PLC ADR press release ( OTCPK:INVVY ): Q2 Non-GAAP EPS of $0.06. Revenue of $221M (+10.0% Y/Y). Outlook: Total FY 2022 expected NR range maintained at $840M to $900M (+10% vs. FY 2021 at the mid-point); Adjusted gross margin expected to be in the low- to mid-8...
News, Short Squeeze, Breakout and More Instantly...
Indivior to Host Analyst Teach-in Event in New York City; Reconfirms Full Year 2024 Guidance PR Newswire RICHMOND, Va. , May 23, 2024 /PRNewswire/ -- Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, announced that in anticipation o...
Indivior Announces Q1 2024 Financial Results PR Newswire SLOUGH, United Kingdom and RICHMOND, Va. , April 25, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024 . The earnings re...
Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone PR Newswire This head-to-head pharmacodynamic study in healthy volunteers...